公开(公告)号：US20120207786A1

公开(公告)日：2012-08-16

申请号：US13297125

申请日：2011-11-15

Applicant: Gale SMITH ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

Inventor： Gale SMITH ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

IPC: A61K39/145 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/14143 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Abstract translation: 本发明公开并要求从具有大流行潜力的病毒中表达和/或含有季节性流感病毒蛋白，禽流感病毒蛋白和/或流感病毒蛋白质的病毒样颗粒（VLPs）。 本发明包括包含所述蛋白质的载体构建体，包含所述构建体的细胞，制剂和包含本发明的VLP的疫苗。 本发明还包括制备和施用VLP到脊椎动物的方法，包括诱导季节性和禽流感的实质性免疫或其至少一种症状的方法。

公开(公告)号：US20110243989A1

公开(公告)日：2011-10-06

申请号：US13054372

申请日：2009-07-17

Applicant: Peter Pushko ,  Igor Lukashevich

Inventor： Peter Pushko ,  Igor Lukashevich

IPC: A61K39/12 ,  C12N15/85 ,  C12N7/04 ,  A61K39/193 ,  A61P37/04 ,  A61P31/14

CPC classification number: A61K39/193 ,  A61K39/12 ,  A61K2039/53 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/24134 ,  C12N2770/24161 ,  C12N2770/36134 ,  C12N2770/36161 ,  Y02A50/388

Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

Abstract translation: 本文描述的是iDNA载体和疫苗及其使用方法。 iDNA在真核细胞中在体外或体内在致病性RNA病毒，特别是黄热病病毒和委内瑞兰马脑炎病毒中产生减毒疫苗。 当将iDNA注射到疫苗接受者中时，活体减毒病毒的RNA通过受体组织中的体内转录产生。 这引发疫苗接种者组织中后代减毒病毒的产生，以及引发保护免受野生型非减毒病毒的有效免疫应答。

公开(公告)号：US20100196419A1

公开(公告)日：2010-08-05

申请号：US12598271

申请日：2008-05-02

Applicant: Richard W. Compans ,  Baozhong Wang ,  Beatrice Hahn ,  Weimin Liu ,  Gale Smith ,  Peter Pushko

Inventor： Richard W. Compans ,  Baozhong Wang ,  Beatrice Hahn ,  Weimin Liu ,  Gale Smith ,  Peter Pushko

IPC: A61K39/12 ,  C07H21/04 ,  C12N15/63 ,  C12N7/01 ,  C12P21/06

CPC classification number: C07K14/43572 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/5258 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/03 ,  C12N9/2442 ,  C12N2710/14022 ,  C12N2740/12022 ,  C12N2740/16023 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16222 ,  C12N2760/10022 ,  C12N2760/16122 ,  C12Y302/01014

Abstract: Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide.

Abstract translation: 本公开的实施方案包括病毒样颗粒，制备病毒样颗粒的方法，包括表达载体，其中与源自未修饰的HIV的VLPs相比，病毒样颗粒可以包含增强的衣壳结合嵌合HN-Env多肽的水平 -env多肽。 病毒样颗粒的实施方案可能具有暴露在其外表面上的Env特异性表位。 在一个实施方案中，暴露在病毒样颗粒的外表面上的Env特异性表位可以与抗HIV-Env特异性抗体特异性结合。 本公开的实施方案还包括产生对HIV-Env多肽的表位特异性的抗体的方法，包括向动物或人类递送有效量的包含嵌合HIV-Eny多肽的病毒样颗粒的悬浮液，由此 诱导对HIV-1烯多肽的表位特异的抗体的形成。

公开(公告)号：US20070184526A1

公开(公告)日：2007-08-09

申请号：US11582540

申请日：2006-10-18

Applicant: Gale Smith ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

Inventor： Gale Smith ,  Rick Bright ,  Peter Pushko ,  Jinyou Zhang ,  Kutub Mahmood

IPC: C12Q1/68 ,  C12P21/06

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/14143 ,  C12N2760/16023 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/16122 ,  C12N2760/16123 ,  C12N2760/16134

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Abstract translation: 本发明公开并要求从具有大流行潜力的病毒中表达和/或含有季节性流感病毒蛋白，禽流感病毒蛋白和/或流感病毒蛋白质的病毒样颗粒（VLPs）。 本发明包括包含所述蛋白质的载体构建体，包含所述构建体的细胞，制剂和包含本发明的VLP的疫苗。 本发明还包括制备和施用VLP到脊椎动物的方法，包括诱导季节性和禽流感的实质性免疫或其至少一种症状的方法。

公开(公告)号：US20060198854A1

公开(公告)日：2006-09-07

申请号：US11319214

申请日：2005-12-28

Applicant: Peter Pushko

Inventor： Peter Pushko

IPC: C07H21/04 ,  A61K39/12

CPC classification number: C12N7/00 ,  A61K2039/5256 ,  C12N2770/36143

Abstract: Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can provide for expression of a heterologous protein or nucleic acid in animal or human cells. In preferred embodiments, the nucleic acid molecules and vector platforms can be safely used to make and administer vaccines or gene therapies.

Abstract translation: 公开了衍生自人类病毒疫苗的核酸分子和载体平台，例如甲病毒病毒疫苗，包括TC-83人疫苗。 这些载体平台可以提供动物或人细胞中异源蛋白质或核酸的表达。 在优选实施方案中，核酸分子和载体平台可以安全地用于制备和施用疫苗或基因治疗。

公开(公告)号：US06517842B1

公开(公告)日：2003-02-11

申请号：US09336910

申请日：1999-06-21

Applicant: Michael C. Hevey ,  Diane L. Negley ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

Inventor： Michael C. Hevey ,  Diane L. Negley ,  Peter Pushko ,  Jonathan F. Smith ,  Alan L. Schmaljohn

IPC: A61K3912

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K16/10 ,  C12N7/00 ,  C12N15/86 ,  C12N2760/14022 ,  C12N2760/14222 ,  C12N2770/36021 ,  C12N2770/36122 ,  C12N2770/36123 ,  C12N2770/36143 ,  C12N2770/36162

Abstract: The invention here relates to recombinant DNA constructs which comprise a Venezuelan equine encephalitis replicon vector and at least one DNA fragment encoding a protective antigen from the Marburg virus. The DNA constructs are useful for inducing an immune response which is protective against infection with Marburg virus in nonhuman primates.

Abstract translation: 本发明涉及包含委内瑞拉马脑炎复制子载体和编码来自马尔堡病毒的保护性抗原的至少一个DNA片段的重组DNA构建体。 DNA构建体可用于诱导在非人类灵长类动物中防止马尔堡病毒感染的免疫应答。

公开(公告)号：US20110245186A1

公开(公告)日：2011-10-06

申请号：US13071398

申请日：2011-03-24

Applicant: Gale Smith ,  Peter Pushko ,  Vittoria Cioce

Inventor： Gale Smith ,  Peter Pushko ,  Vittoria Cioce

IPC: A61K38/16 ,  C07K14/435 ,  C12N15/12 ,  C12N7/00 ,  C12N15/63 ,  C12N5/07 ,  C12N1/21 ,  C12P21/00 ,  A61K31/7052 ,  A61P29/00

CPC classification number: C07K14/70564 ,  A61K38/00

Abstract: The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.

Abstract translation: 本发明的特征包括重组哺乳动物E-选择蛋白肽，编码所述肽的核酸，具有这些核酸的载体和细胞，以及制备肽的方法。 其它发明特征包括使用重组哺乳动物E-选择蛋白肽治疗与炎症相关的疾病和病症以诱导对E-选择素的粘膜耐受的方法。

公开(公告)号：US20100247574A1

公开(公告)日：2010-09-30

申请号：US12527844

申请日：2008-02-21

Applicant: Kutub Mahmood ,  Gale Smith ,  Peter Pushko

Inventor： Kutub Mahmood ,  Gale Smith ,  Peter Pushko

IPC: A61K39/17 ,  C07K19/00 ,  A61P31/14 ,  C12P21/06

CPC classification number: C12N7/00 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2710/14143 ,  C12N2760/18122 ,  C12N2760/18123 ,  Y02A50/386

Abstract: The present invention discloses and claims chimeric virus like particles (VLPs) that express and/or contains Newcastle disease matrix protein. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising chimeric VLPs of the inventions. The invention also includes methods of making and administrating chimeric VLPs to vertebrates, including methods of inducing immunity to infections.

Abstract translation: 本发明公开并要求表达和/或含有新城疫基质蛋白的嵌合病毒样颗粒（VLP）。 本发明包括包含所述蛋白质的载体构建体，包含所述构建体的细胞，包含本发明的嵌合VLP的制剂和疫苗。 本发明还包括制备和给予脊椎动物嵌合VLP的方法，包括诱导感染免疫的方法。

公开(公告)号：US20090017066A1

公开(公告)日：2009-01-15

申请号：US12127625

申请日：2008-05-27

Applicant: Gale Smith ,  Peter Pushko ,  Kutub Mahmood ,  Bin Zhao

Inventor： Gale Smith ,  Peter Pushko ,  Kutub Mahmood ,  Bin Zhao

IPC: A61K39/145 ,  C07K14/11 ,  A61P31/16 ,  C12P21/02

CPC classification number: A61K39/145 ,  A61K2039/5258 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/16723 ,  C12N2760/16123

Abstract: The present invention discloses novel influenza virus-like particles (VLPs) that contain chimeric proteins or influenza membrane proteins. The chimeric proteins are derived from fragments of influenza membrane proteins fused to heterologous proteins. The invention includes antigenic formulations and vaccines comprising VLPs of the invention as well as methods of making and administering VLPs to vertebrates, including methods of inducing immunity to infections, such as influenza.

Abstract translation: 本发明公开了含有嵌合蛋白或流感病毒膜蛋白的新型流感病毒样颗粒（VLPs）。 嵌合蛋白质衍生自与异源蛋白质融合的流感病毒膜蛋白片段。 本发明包括抗原制剂和包含本发明的VLP的疫苗以及向脊椎动物制备和施用VLP的方法，包括诱导感染免疫的方法，例如流感。

公开(公告)号：US20080233150A1

公开(公告)日：2008-09-25

申请号：US11941768

申请日：2007-11-16

Applicant: Gale SMITH ,  Peter Pushko ,  Mike Massare ,  Yingyun Wu ,  Kutub Mahmood

Inventor： Gale SMITH ,  Peter Pushko ,  Mike Massare ,  Yingyun Wu ,  Kutub Mahmood

IPC: A61K39/155 ,  A61P31/12 ,  C07K16/00

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2760/18522 ,  C12N2760/18523 ,  C12N2760/18534 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/394

Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains RSV proteins. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing immunity to infections, including RSV.

Abstract translation: 本发明公开并要求表达和/或含有RSV蛋白质的病毒样颗粒（VLP）。 本发明包括包含所述蛋白质的载体构建体，包含所述构建体的细胞，制剂和包含本发明的VLP的疫苗。 本发明还包括制备和施用VLP到脊椎动物的方法，包括诱导感染免疫的方法，包括RSV。